Validating the interval to biochemical failure for the identification of potentially lethal prostate cancer

Journal of Clinical Oncology

Volumn 30, Issue 15, 2012, Pages 1857-1863

  Buyyounouski, Mark K ^a   Pickles, Tom ^b   Kestin, Larry L ^c   Allison, Roger ^d   Williams, Scott G ^e  

^a FOX CHASE CANCER CENTER   (United States)

^b BRITISH COLUMBIA CANCER AGENCY   (Canada)

^c 21ST CENTURY ONCOLOGY   (United States)

^d ROYAL BRISBANE AND WOMEN'S HOSPITAL   (Australia)

^e PETER MACCALLUM CANCER CENTRE   (Australia)

Author keywords

[No Author keywords available]

Indexed keywords

PROSTATE SPECIFIC ANTIGEN;

ADULT; AGED; ARTICLE; BIOCHEMICAL FAILURE FREE SURVIVAL; CANCER INCIDENCE; CANCER MORTALITY; CONTROLLED STUDY; DIAGNOSTIC TEST ACCURACY STUDY; FOLLOW UP; HUMAN; MAJOR CLINICAL STUDY; MALE; OUTCOME ASSESSMENT; PREDICTIVE VALIDITY; PRIORITY JOURNAL; PROGNOSIS; PROSTATE CANCER; SENSITIVITY ANALYSIS; SENSITIVITY AND SPECIFICITY; VALIDATION STUDY;

AGED; AGED, 80 AND OVER; AUSTRALIA; CANADA; DISCRIMINANT ANALYSIS; DISEASE PROGRESSION; HUMANS; MALE; MIDDLE AGED; MODELS, STATISTICAL; PREDICTIVE VALUE OF TESTS; PROSTATE-SPECIFIC ANTIGEN; PROSTATIC NEOPLASMS; REPRODUCIBILITY OF RESULTS; RISK ASSESSMENT; RISK FACTORS; SENSITIVITY AND SPECIFICITY; SURVIVAL ANALYSIS; TIME FACTORS; TREATMENT FAILURE; UNITED STATES; UP-REGULATION;

EID: 84863886222     PISSN: 0732183X     EISSN: 15277755     Source Type: Journal    
DOI: 10.1200/JCO.2011.35.1924     Document Type: Article

References (32)

1. Roach M 3rd, Hanks G, Thames H Jr, et al: Defining biochemical failure following radiotherapy with or without hormonal therapy in men with clinically localized prostate cancer: Recommendations of the RTOG-ASTRO Phoenix Consensus Conference. Int J Radiat Oncol Biol Phys 65:965-974, 2006
2. Buyyounouski MK, Hanlon AL, Eisenberg DF, et al: Defining biochemical failure after radiotherapy with and without androgen deprivation for prostate cancer. Int J Radiat Oncol Biol Phys 63:1455-1462, 2005 (Pubitemid 41628042)
3. Kestin LL, Vicini FA, Martinez AA: Practical application of biochemical failure definitions: What to do and when to do it. Int J Radiat Oncol Biol Phys 53:304-315, 2002 (Pubitemid 34525101)
4. Vicini FA, Kestin LL, Martinez AA: The correlation of serial prostate specific antigen measurements with clinical outcome after external beam radiation therapy of patients for prostate carcinoma. Cancer 88:2305-2318, 2000 (Pubitemid 30247131)
5. Thames H, Kuban D, Levy L, et al: Comparison of alternative biochemical failure definitions based on clinical outcome in 4839 prostate cancer patients treated by external beam radiotherapy between 1986 and 1995. Int J Radiat Oncol Biol Phys 57:929-943, 2003 (Pubitemid 37324110)
6. Horwitz EM, Thames HD, Kuban DA, et al: Definitions of biochemical failure that best predict clinical failure in patients with prostate cancer treated with external beam radiation alone: A multi-institutional pooled analysis. J Urol 173:797-802, 2005 (Pubitemid 40239344)
7. Williams SG: Characterization of the behavior of three definitions of prostate-specific antigen-based biochemical failure in relation to detection and follow-up biases: Comparison with the American Society for Therapeutic Radiology and Oncology consensus definition. Int J Radiat Oncol Biol Phys 64:849-855, 2006
8. Pickles T, Kim-Sing C, Morris WJ, et al: Evaluation of the Houston biochemical relapse definition in men treated with prolonged neoadjuvant and adjuvant androgen ablation and assessment of follow-up lead-time bias. Int J Radiat Oncol Biol Phys 57:11-18, 2003 (Pubitemid 36959733)
9. Coen JJ, Chung CS, Shipley WU, et al: Influence of follow-up bias on PSA failure after external beam radiotherapy for localized prostate cancer: Results from a 10-year cohort analysis. Int J Radiat Oncol Biol Phys 57:621-628, 2003 (Pubitemid 37194287)
10. D'Amico AV, Moul J, Carroll PR, et al: Prostate specific antigen doubling time as a surrogate end point for prostate cancer specific mortality following radical prostatectomy or radiation therapy. J Urol 172:S42-S46, 2004
11. Zietman AL, Christodouleas JP, Shipley WU: PSA bounces after neoadjuvant androgen deprivation and external beam radiation: Impact on definitions of failure. Int J Radiat Oncol Biol Phys 62:714-718, 2005 (Pubitemid 40779759)
12. Ray ME, Thames HD, Levy LB, et al: PSA nadir predicts biochemical and distant failures after external beam radiotherapy for prostate cancer: A multi-institutional analysis. Int J Radiat Oncol Biol Phys 64:1140-1150, 2006
13. Zelefsky MJ, Shi W, Yamada Y, et al: Postra-diotherapy 2-year prostate-specific antigen nadir as a predictor of long-term prostate cancer mortality. Int J Radiat Oncol Biol Phys 75:1350-1356, 2009
14. Alcantara P, Hanlon A, Buyyounouski MK, et al: Prostate-specific antigen nadir within 12 months of prostate cancer radiotherapy predicts metastasis and death. Cancer 109:41-47, 2007 (Pubitemid 46120193)
15. D'Amico AV, Moul JW, Carroll PR, et al: Surrogate end point for prostate cancer-specific mortality after radical prostatectomy or radiation therapy. J Natl Cancer Inst 95:1376-1383, 2003 (Pubitemid 37220457)
16. Buyyounouski MK, Hanlon AL, Horwitz EM, et al: Interval to biochemical failure highly prognostic for distant metastasis and prostate cancer-specific mortality after radiotherapy. Int J Radiat Oncol Biol Phys 70:59-66, 2008 (Pubitemid 350251025)
17. Valicenti RK, DeSilvio M, Hanks GE, et al: Posttreatment prostatic-specific antigen doubling time as a surrogate endpoint for prostate cancer-specific survival: An analysis of Radiation Therapy Oncology Group Protocol 92-02. Int J Radiat Oncol Biol Phys 66:1064-1071, 2006 (Pubitemid 44633505)
18. Arlen PM, Bianco F, Dahut WL, et al: Prostate Specific Antigen Working Group guidelines on prostate specific antigen doubling time. J Urol 179:2181-2185, 2008
19. Ramírez ML, Nelson EC, Devere White RW, et al: Current applications for prostate-specific antigen doubling time. Eur Urol 54:291-300, 2008
20. Kestin LL, Goldstein NS, Vicini FA, et al: Percentage of positive biopsy cores as predictor of clinical outcome in prostate cancer treated with radiotherapy. J Urol 168:1994-1999, 2002
21. Williams SG, Buyyounouski MK, Pickles T, et al: Percentage of biopsy cores positive for malignancy and biochemical failure following prostate cancer radiotherapy in 3,264 men: Statistical significance without predictive performance. Int J Radiat Oncol Biol Phys 70:1169-1175, 2008 (Pubitemid 351296120)
22. Williams SG, Taylor JM, Liu N, et al: Use of individual fraction size data from 3756 patients to directly determine the alpha/beta ratio of prostate cancer. Int J Radiat Oncol Biol Phys 68:24-33, 2007 (Pubitemid 46589844)
23. Mohler J, Bahnson RR, Boston B, et al: NCCN clinical practice guidelines in oncology: Prostate cancer. J Natl Compr Canc Netw 8:162-200, 2010
24. Kennedy EH, Taylor JM, Schaubel DE, et al: The effect of salvage therapy on survival in a longitudinal study with treatment by indication. Stat Med 29:2569-2580, 2010
25. Heagerty PJ, Zheng Y: Survival model predictive accuracy and ROC curves. Biometrics 61:92-105, 2005 (Pubitemid 40380968)
26. Pencina MJ, D'Agostino RB Sr, D'Agostino RB Jr, et al: Evaluating the added predictive ability of a new marker: From area under the ROC curve to reclassification and beyond. Stat Med 27:157-172, 2008; discussion 207-12
27. Schemper M, Smith TL: A note on quantifying follow-up in studies of failure time. Control Clin Trials 17:343-346, 1996 (Pubitemid 26342716)
28. Harrell FE Jr, Lee KL, Mark DB: Multivariable prognostic models: Issues in developing models, evaluating assumptions and adequacy, and measuring and reducing errors. Stat Med 15:361-387, 1996 (Pubitemid 26072233)
29. Freedland SJ, Humphreys EB, Mangold LA, et al: Risk of prostate cancer-specific mortality following biochemical recurrence after radical prostatectomy. JAMA 294:433-439, 2005 (Pubitemid 41124175)
30. Lee AK, Levy LB, Cheung R, et al: Prostate-specific antigen doubling time predicts clinical outcome and survival in prostate cancer patients treated with combined radiation and hormone therapy. Int J Radiat Oncol Biol Phys 63:456-462, 2005 (Pubitemid 41317162)
31. Buyyounouski M, Kestin L, Duchesne G, et al: A nomogram predicting 5-year probability of cause specific survival from biochemical failure following radiotherapy. Int J Radiat Oncol Biol Phys 81:S389, 2011
32. Stephenson AJ, Kattan MW, Eastham JA, et al: Prostate cancer-specific mortality after radical prostatectomy for patients treated in the prostate-specific antigen era. J Clin Oncol 27:4300-4305, 2009